I
ncreasing evidence shows that the transforming growth factor (TGF) superfamily, especially TGF-␤1, plays a critical role in angiogenesis, wound healing, and inflammation. The TGF-␤ superfamily of structurally related peptides includes the TGF-␤ isoforms (␤1, ␤2, ␤3, and ␤ 4 ), the activins, and the bone morphogenetic proteins. 1,2 TGF-␤s exert their effects by binding to specific receptors, including receptors type 1, type 2, ␤-glycan, and endoglin. 3, 4 The molecular mechanism of the receptor 1/receptor 2 interplay in response to TGF-␤ has been well elucidated. 5, 6 ␤-Glycan has been shown to potentiate the binding of the ligand to cells. 7 Endoglin has been shown to modulate the signals transmitted by the receptor complex. 8 Endoglin (CD105) is a homodimeric integral membrane glycoprotein composed of disulfide-linked subunits of 90 to 95 kDa. In humans, it is expressed at high levels on vascular endothelial cells. 9 Endoglin plays a key role in angiogenesis, inasmuch as inhibition of its expression markedly attenuates angiogenesis in vitro. 10 Another study 11 showed that mice lacking endoglin die from defective vascular development, whereas mice lacking TGF-␤ have normal vascular growth. Angiotensin (Ang) II has been known to be a key factor in hypertension, atherosclerosis, and coronary heart disease. Ang II induces apoptosis of endothelial cells 12 and enhances the proliferation of smooth muscle cells. 13 Experimental and clinical studies 14, 15 show that Ang II plays a critical role in the remodeling of blood vessels and myocardium after acute myocardial infarction. The biological function of Ang II is mainly mediated by its type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The activation of Ang II receptors causes activation of intracellular signals, such as protein kinase C, mitogen-activated protein kinase (MAPK), and nuclear factor (NF)-B, a transcription factor.
Previous studies 16 -19 have suggested an important interaction between Ang II and TGF-␤1. Ang II increases TGF-␤1 synthesis in fibroblasts, smooth muscle cells, and renal mesangial cells. The present study was designed to observe the effect of Ang II on the expression of endoglin (mRNA and protein) and the signal transduction pathway in this process in human coronary artery endothelial cells (HCAECs). We also examined the Ang II-mediated regulation of other TGF-␤1 receptors and immunoreactive TGF-␤1 in HCAECs.
Methods

Cell Culture and Study Design
The culture of HCAECs was described earlier by us. 20 HCAECs were incubated with Ang II (10 Ϫ8 to 10 Ϫ5 mol/L) for 6, 12, and 24 hours to determine the expression of endoglin. In other experiments, HCAECs were pretreated with the specific AT 1 receptor inhibitor losartan (10 Ϫ6 mol/L) or the specific AT 2 receptor inhibitor PD 123,319 (10 Ϫ6 mol/L) for 30 minutes, and then the cells were exposed to Ang II to determine the receptor specificity of the effect of Ang II. HCAECs were also pretreated with the MAPK inhibitor PD 098,059 (10 Ϫ5 mol/L) and then exposed to Ang II to explore the signaling pathway of the effect of Ang II on endoglin expression. The concentration of all reagents and the duration of incubation were decided on the basis of previous studies. 12, 20 To observe the regulation of TGF-␤1 type 1 and 2 receptors, HCAECs were incubated with Ang II (10 Ϫ8 to 10 Ϫ6 mol/L) for 24 hours. HCAECs were pretreated with losartan or PD 123,319 (10 Ϫ6 mol/L) to determine the receptor specificity of Ang II action in the expression of TGF-␤1 type 1 and 2 receptors. Immunoreactive TGF-␤1 was also measured in these experiments.
Semiquantitative Reverse Transcription-PCR for TGF-␤1 Receptor mRNA
Total RNA (1 g) extracted from cultured HCAECs was reversetranscribed with oligo(dT) (Promega) and M-MLV reverse transcriptase (Promega) at 37°C for 1 hour. Amplification of TGF-␤1 type 1 and type 2 receptors and endoglin was achieved by using specific primers (see the Table) . The products of polymerase chain reaction (PCR) were visualized on 1.5% agarose gels with the use of ethidium bromide. mRNA bands were normalized with ␤-actin mRNA bands. The relative intensity of the band of interest was analyzed by UN-SCAN-IT gel software (Silk Scientific) and expressed as the ratio of the band of interest to the ␤-actin mRNA band. 20, 21 Western Analysis for TGF-␤1 Receptor Protein HCAEC lysates were separated and transferred to nitrocellulose membranes. After they were blocked, the membranes were incubated with 1:1000 dilution endoglin antibody (DAKO). Membranes were then incubated with 1:2000 dilution second antibody, and the membranes were detected with the enhanced chemiluminescence system. 20, 21 To determine the expression of TGF-␤1 type 1 and 2 receptors, HCAEC lysate (500 g) was immunoprecipitated and then subjected to Western analysis. Antibodies to TGF-␤1 type 1 and 2 receptors (Santa Cruz Biotechnology) were used in 1:1000 dilution.
Measurement of TGF-␤1 Activity
TGF-␤1 activity in culture medium was measured with an ELISA kit (Promega). The technique for ELISA was the same as that recommended by the manufacturer, with absorbance determination at 450 nm. TGF-␤1 activity was expressed as picograms per milligram protein.
Determination of MAPK Phosphorylation
HCAEC lysates were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. After they were blocked, the membranes were incubated with 1:1000 dilution phospho-specific MAPK antibodies (Calbiochem) that detect p 42MAPK and p
44MAPK
. Thereafter, the membrane was stripped and reprobed with MAPK antibody. 22 
Data Analysis
All data (meanϮSD) represent the mean of 6 independent experiments. Statistical significance was determined in multiple comparisons among groups of data in which ANOVA and the F test indicated the presence of significant differences. A value of PՅ0.05 was considered significant. 
Results
Ang II and Expression of Endoglin
Ang II Receptor Subtypes and Endoglin Expression
To determine the role of Ang II receptors in endoglin expression, HCAECs were pretreated with the specific AT 1 receptor blocker losartan (10 Ϫ6 mol/L) or the AT 2 receptor blocker PD 123,319 (10 Ϫ6 mol/L) for 30 minutes, and then the cells were exposed to Ang II (10 Ϫ6 mol/L) for 24 hours. We found that the AT 1 receptor blocker losartan completely blocked the effect of Ang II on endoglin mRNA and protein expression, whereas the AT 2 receptor blocker PD 123,319 had no effect on Ang II-induced endoglin expression (Figure 3 ). 
Primer Sequences, Amplification Conditions, and Product Length of Analyzed Genes
Li et al Angiotensin II and Endoglin
Intracellular Signal Transduction
To determine intracellular signal in the effect of Ang II on endoglin expression, we examined the activation of intracellular MAPK. Incubation of HCAECs with Ang II had no effect on MAPK protein, but it caused an increase in activated MAPK (determined by phosphorylation of MAPK) compared with control (PϽ0.01). Most important, losartan inhibited Ang II-induced activation of MAPK, whereas PD 123,319 had no effect. Pretreatment of HCAECs with a specific MAPK inhibitor, PD 098,059, fully blocked Ang II-induced activation of MAPK (Figure 4) . Finally, we found that pretreatment of cells with PD 098,059, the specific MAPK inhibitor, inhibited the expression of Ang II-induced endoglin mRNA and protein (Figure 3 ).
Ang II and Expression of TGF-␤1 Type 1 and 2 Receptors
Incubation of HCAECs with Ang II also induced the expression of TGF-␤1 receptor type 1 and 2 mRNA and protein in a concentration (10 Ϫ8 to 10 Ϫ6 mol/L)-dependent manner. The maximal effect of Ang II was observed with 10 Ϫ6 mol/L concentration. The effect of Ang II was mediated by activation of the AT 1 receptor but not the AT 2 receptor, inasmuch as losartan, but not PD 123,319, blocked the Ang II-induced upregulation of TGF-␤1 type 1 and 2 receptor expression ( Figure 5 ).
Ang II and TGF-␤1 Levels
Incubation of HCAECs with Ang II decreased the expression of TGF-␤1 levels in a concentration (10 Ϫ8 to 10 Ϫ6 mol/L)-dependent manner. Again, pretreatment of HCAECs with losartan, but not PD 123,319, prevented the Ang II-induced decrease in TGF-␤1 levels ( Figure 6 ).
Discussion
The present study shows that Ang II markedly upregulates the expression of endoglin. This effect of Ang II is mediated by activation of its AT 1 receptor. The activation of MAPK elicited by Ang II appears to be a critical signaling pathway, because PD 098,059, the specific MAPK inhibitor, blocked the upregulation of endoglin expression in response to Ang II. The present study also shows that Ang II via AT 1 activation increases the expression of TGF-␤1 type 1 and 2 receptors. We also found that as receptor expression increased in response to Ang II, TGF-␤1 release by HCAECs decreased.
Interaction Between Ang II and TGF-␤1
Both Ang II and TGF-␤1 are pleiotropic factors in the cardiovascular system. Physiological levels of Ang II play an important role in the maintenance of blood pressure. High levels of Ang II induce endothelial dysfunction, 12 vasoconstriction, and proliferation of smooth muscle cells. 13 These effects of Ang II, mediated predominantly by AT 1 receptor activation, contribute to the development of hypertension and atherosclerosis. The role of TGF-␤1 in vascular growth has gained increasing attention in recent years. TGF-␤1 plays an important role in the maintenance of blood vessel integrity. 23, 24 Recent studies from our laboratory have demonstrated that TGF-␤1 inhibits apoptosis of cardiac myocytes induced by hypoxia/reoxygenation 25 and modulates myocardial injury after a brief period of ischemia/reperfusion. 26 On the other hand, other studies have shown that TGF-␤1 promotes the development of atherosclerosis 27 and restenosis after angioplasty. 28 Recent studies 16 -19 indicate that there is an important interaction between Ang II and TGF-␤1. Kupfahl et al 16 have demonstrated that Ang II directly increases the expression of TGF-␤1 in the human heart. Motajima et al 18 have shown that TGF-␤1 upregulates Ang II-induced plasminogen activator inhibitor mRNA. These facilitative interactions between Ang II and TGF-␤1 lead to the development of atherosclerosis and vascular injury. In contrast to the increase in TGF-␤1 synthesis in smooth muscle cells in response to Ang II, 29 we observed that Ang II decreases TGF-␤1 levels in HCAECs. This unique effect of Ang II in endothelial cells may reflect the binding of TGF-␤1 to upregulated TGF-␤1 receptors. Another potential mechanism for decrease in immunoreactive levels of TGF-␤1 is the downregulation of its synthesis, inasmuch as the expression of TGF-␤1 receptors increases dramatically when endothelial cells are exposed to Ang II. Nonetheless, the contrasting effects of Ang II relative to the release of TGF-␤1 in endothelial cells and smooth muscle cells must await further work.
Ang II and Its Receptors and Expression of TGF-␤1 Receptors
Recent molecular genetic studies in humans and mice have shown that TGF-␤1 is involved in vasculogenesis and the maintenance of blood vessel integrity. 23, 24 There is significant alternation in the expression of TGF-␤1 type 1 and 2 receptors in atherosclerotic tissues. 30, 31 Experimental studies 10, 11 have shown endoglin to be a critical factor in angiogenesis, which is a feature of atherosclerosis. Li et al 10 have demonstrated that endoglin, highly expressed in endothelial cells, markedly antagonizes the inhibitory effects of TGF-␤1 on the formation of capillary tubes and thus contributes to the proliferation, migration, and capillary formation. Another study 11 found that the deficiency of endoglin leads to death by gestational day 11 from defective vascular development in mice. These observations collectively suggest that the endoglin receptor plays an important role in vascular growth.
Ang II is well known to be a critical factor in atherosclerosis. Ang II activates the AT 1 receptor and then induces vasoconstriction, apoptosis of endothelial cells, 12 proliferation of smooth muscle cells, 13 and recruitment of monocytes. 32 Ang II exerts a proatherogenic effect synergistically with other mitogenic factors. For instance, Ang II markedly induces the oxidation of LDLs, 33 stimulates the uptake of oxidized LDLs, and facilitates the expression of the oxidized LDL receptor LOX-1. 20 In the present study, we found that Ang II significantly upregulates the expression of TGF-␤1 receptors (endoglin as well as types 1 and 2). Notably, we found that the Ang II-induced upregulation of endoglin expression was completely blocked by the AT 1 receptor blocker losartan but not by the AT 2 receptor blocker PD 123,319. These observations indicate a novel mechanism by which Ang II may regulate angiogenesis and remodeling of the blood vessels and cardiac tissues. These observations gain support from findings indicating that AT 1 receptor blockers, such as losartan, markedly attenuate the development of atherosclerosis and the remodeling of infarcted myocardium. 34, 35 
Signal Transduction Mechanism of Ang II-Induced Endoglin Upregulation
Ang II exerts its biological effects via activation of different signal transduction pathways, such as protein kinase C 12 and MAPK. 36 The MAPK cascade is a signal transduction pathway that mediates many changes in cell biology. Activation of MAPK causes the activation of transcription factors, such as NF-B and activator protein-1. 37, 38 In the present study, we confirmed the activation of MAPK by Ang II in HCAECs. This effect of Ang II was mediated by the AT 1 receptor, because losartan fully blocked the activation of MAPK. Most important, we found that the specific MAPK inhibitor PD 098,059 not only inhibited the activation of MAPK but also inhibited the endoglin expression induced by Ang II, indicating a critical role of MAPK activation as a signaling mechanism.
Summary
The present study provides clear evidence that Ang II induces the expression of endoglin by activation of the AT 1 receptor in HCAECs. In this process, the activation of MAPK plays an important role in signal transduction. Ang II via AT 1 activation also increases the expression of TGF-␤1 type 1 and type 2 receptors. These observations provide a novel insight into the role of Ang II in the pathobiology of vascular remodeling. These studies in human coronary endothelial cells may be relevant to atherogenesis and vascular growth in humans. Ϫ6 mol/L. Again, the AT 1 receptor blocker losartan inhibited the effect of Ang II, whereas the AT 2 receptor blocker PD 123,319 had no effect. Summarized data (meanϮSD) from 6 separated experiments are shown.
